Dimensional Fund Advisors LP boosted its holdings in Retrophin, Inc. (NASDAQ:RTRX) by 49.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 825,253 shares of the biopharmaceutical company’s stock after purchasing an additional 271,551 shares during the quarter. Dimensional Fund Advisors LP owned about 2.16% of Retrophin worth $16,002,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Parametric Portfolio Associates LLC grew its position in Retrophin by 3.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,471 shares of the biopharmaceutical company’s stock valued at $649,000 after purchasing an additional 1,200 shares during the period. Vanguard Group Inc. grew its position in Retrophin by 8.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,635,234 shares of the biopharmaceutical company’s stock valued at $31,707,000 after purchasing an additional 125,695 shares during the period. Northern Trust Corp grew its position in Retrophin by 3.8% in the 2nd quarter. Northern Trust Corp now owns 708,248 shares of the biopharmaceutical company’s stock valued at $13,732,000 after purchasing an additional 26,119 shares during the period. GSA Capital Partners LLP acquired a new stake in Retrophin in the 2nd quarter valued at $279,000. Finally, Emory University acquired a new stake in Retrophin in the 2nd quarter valued at $1,767,000.
In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total transaction of $31,005.00. Following the transaction, the chief operating officer now directly owns 13,622 shares in the company, valued at approximately $306,495. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.41% of the stock is currently owned by company insiders.
Retrophin, Inc. (NASDAQ RTRX) opened at $21.75 on Friday. The company has a quick ratio of 3.96, a current ratio of 3.88 and a debt-to-equity ratio of 0.15. Retrophin, Inc. has a 52 week low of $15.55 and a 52 week high of $26.44.
Retrophin (NASDAQ:RTRX) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.21). Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The company had revenue of $40.34 million for the quarter, compared to the consensus estimate of $40.51 million. During the same quarter last year, the business posted ($0.09) earnings per share. Retrophin’s revenue was up 18.8% on a year-over-year basis. equities analysts predict that Retrophin, Inc. will post -1.25 earnings per share for the current year.
Several research firms recently issued reports on RTRX. ValuEngine downgraded shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. BMO Capital Markets reissued a “buy” rating and issued a $44.00 price target on shares of Retrophin in a research report on Friday, October 6th. Finally, BidaskClub raised shares of Retrophin from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $36.00.
ILLEGAL ACTIVITY NOTICE: “Dimensional Fund Advisors LP Boosts Position in Retrophin, Inc. (RTRX)” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/11/12/dimensional-fund-advisors-lp-boosts-position-in-retrophin-inc-rtrx.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.